IsoPlexis bags $25M to stoke T cell therapy buzz; Collaboration between X4 and LLS; New CMO at Precision Biosciences
→ Riding on the buzz around T cell therapies from CAR-T and TCR to CRISPR-based approaches, IsoPlexis has raised $25 million to advance its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
